Terms: = Colorectal cancer AND MUC16, CA125, CA-125 AND Staging
19 results:
1. Construction and validation of artificial intelligence pathomics models for predicting pathological staging in colorectal cancer: Using multimodal data and clinical variables.
Tan Y; Liu R; Xue JW; Feng Z
Cancer Med; 2024 Apr; 13(7):e6947. PubMed ID: 38545828
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic role of metabolic 18F-FDG PET/CT parameters and hematological prognostic indicators in patients with colorectal cancer.
Cengiz A; Yersal Ö; Ömürlü İK; Yürekli Y
Indian J Cancer; 2023; 60(2):224-229. PubMed ID: 37530245
[TBL] [Abstract] [Full Text] [Related]
3. Tumour genotypes account for survival differences in right- and left-sided colon cancers.
Ward TM; Cauley CE; Stafford CE; Goldstone RN; Bordeianou LG; Kunitake H; Berger DL; Ricciardi R
Colorectal Dis; 2022 May; 24(5):601-610. PubMed ID: 35142008
[TBL] [Abstract] [Full Text] [Related]
4. BH-index: A predictive system based on serum biomarkers and ensemble learning for early colorectal cancer diagnosis in mass screening.
Battista A; Battista RA; Battista F; Iovane G; Landi RE
Comput Methods Programs Biomed; 2021 Nov; 212():106494. PubMed ID: 34740064
[TBL] [Abstract] [Full Text] [Related]
5. High-risk Stage III colon cancer patients identified by a novel five-gene mutational signature are characterized by upregulation of IL-23A and gut bacterial translocation of the tumor microenvironment.
Ge W; Hu H; Cai W; Xu J; Hu W; Weng X; Qin X; Huang Y; Han W; Hu Y; Yu J; Zhang W; Ye S; Qi L; Huang P; Chen L; Ding K; Wang LD; Zheng S
Int J Cancer; 2020 Apr; 146(7):2027-2035. PubMed ID: 31693169
[TBL] [Abstract] [Full Text] [Related]
6. [Clinicopathological characteristics of type 2 diabetes mellitus complicated with colorectal cancer].
Han ZH; Chen JJ; Feng N; Niu PF; Song C; Gao ZY; Gao QK; Ji DB; Wang WB; Lei FM; Gu J
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Oct; 22(10):966-971. PubMed ID: 31630495
[No Abstract] [Full Text] [Related]
7. [Correlation of ¹⁸F-FDG PET-CT maximum standard uptake value and T/N ratio with the prognosis of postoperative colorectal cancer].
Wang X; Peng G; Zhang X; Chen Z; Zhang B; Li Z
Zhonghua Wei Chang Wai Ke Za Zhi; 2015 Mar; 18(3):232-7. PubMed ID: 25809325
[TBL] [Abstract] [Full Text] [Related]
8. Recent progress in the diagnosis and treatment of ovarian cancer.
Jelovac D; Armstrong DK
CA Cancer J Clin; 2011; 61(3):183-203. PubMed ID: 21521830
[TBL] [Abstract] [Full Text] [Related]
9. Analysis of hMLH1 and hMSH2 expression in cisplatin-treated ovarian cancer patients.
Magnowska M; Surowiak P; Nowak-Markwitz E; Michalak M; Magnowski P; Rokita W; Kedzia H; Zabel M; Spaczyński M
Ginekol Pol; 2008 Dec; 79(12):826-34. PubMed ID: 19175039
[TBL] [Abstract] [Full Text] [Related]
10. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
Sturgeon CM; Duffy MJ; Stenman UH; Lilja H; Brünner N; Chan DW; Babaian R; Bast RC; Dowell B; Esteva FJ; Haglund C; Harbeck N; Hayes DF; Holten-Andersen M; Klee GG; Lamerz R; Looijenga LH; Molina R; Nielsen HJ; Rittenhouse H; Semjonow A; Shih IeM; Sibley P; Sölétormos G; Stephan C; Sokoll L; Hoffman BR; Diamandis EP;
Clin Chem; 2008 Dec; 54(12):e11-79. PubMed ID: 19042984
[TBL] [Abstract] [Full Text] [Related]
11. Normal and modified urinary nucleosides represent novel biomarkers for colorectal cancer diagnosis and surgery monitoring.
Feng B; Zheng MH; Zheng YF; Lu AG; Li JW; Wang ML; Ma JJ; Xu GW; Liu BY; Zhu ZG
J Gastroenterol Hepatol; 2005 Dec; 20(12):1913-9. PubMed ID: 16336453
[TBL] [Abstract] [Full Text] [Related]
12. [Application of urinary nucleosides in the diagnosis and surgical monitoring of colorectal cancer].
Feng B; Zheng MH; Zheng YF; Lu AG; Li JW; Wang ML; Ma JJ; Xu GW; Yu BM
Zhonghua Wai Ke Za Zhi; 2005 May; 43(9):564-8. PubMed ID: 15938925
[TBL] [Abstract] [Full Text] [Related]
13. [Gastrointestinal cancer].
Takahashi Y
Gan To Kagaku Ryoho; 2004 Aug; 31(8):1275-9. PubMed ID: 15332558
[TBL] [Abstract] [Full Text] [Related]
14. OVX1 and CEA in patients with colon carcinoma, colon polyps and benign colon disorders.
Martell RE; Xu FJ; Davis WZ; Anselmino L; Yu YH; Daly L; Bast RC
Int J Biol Markers; 1998; 13(3):145-9. PubMed ID: 10079388
[TBL] [Abstract] [Full Text] [Related]
15. Current status of staging laparotomy in colorectal and ovarian cancer.
Boente MP; Yeh K; Hogan WM; Ozols RF
Cancer Treat Res; 1996; 82():337-57. PubMed ID: 8849961
[TBL] [Abstract] [Full Text] [Related]
16. [Application of whole layer core biopsy of bladder wall to paravesical tumor].
Hoshi S; Orikasa S; Suzuki K; Kaneda T; Konda R; Maehara I; Kato H
Hinyokika Kiyo; 1994 Nov; 40(11):981-5. PubMed ID: 7832084
[TBL] [Abstract] [Full Text] [Related]
17. Tumor markers, liver function tests and symptoms in 115 patients with isolated colorectal liver metastases.
Lorenz M; Baum RP; Oremek G; Inglis R; Reimann-Kirkowa M; Hör G; Seiffert U; Hottenrott C
Int J Biol Markers; 1989; 4(1):18-26. PubMed ID: 2746045
[TBL] [Abstract] [Full Text] [Related]
18. Radioimmunoscintigraphy using monoclonal antibodies to CEA, CA 19-9 and CA 125.
Baum RP; Lorenz M; Hottenrott C; Albrecht M; Senekowitsch R; Happ J; Hertel A; Spitz J; Hör G
Int J Biol Markers; 1988; 3(3):177-84. PubMed ID: 3230337
[TBL] [Abstract] [Full Text] [Related]
19. Clinical usefulness of three monoclonal antibody-defined tumor markers: CA 19-9, CA 50, and CA 125.
Szymendera JJ
Tumour Biol; 1986; 7(5-6):333-42. PubMed ID: 2437641
[TBL] [Abstract] [Full Text] [Related]
